Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 1214 results

Media Release / Oct 10, 2015
Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years
Late-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with CosentyxTM after three years[1] 6 out of 10 patients (64%) had…
Media Release / Oct 08, 2015
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
NEDA-4 - no evidence of disease activity based on four parameters - relapses, MRI lesions, brain shrinkage and disability progression - is a comprehensive measure of MS disease control 31.2%…
Media Release / Oct 05, 2015
Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery
AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps maintain integrity of incision while facilitating smooth IOL delivery Follows earlier FDA approval…
Media Release / Oct 02, 2015
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
Etanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the…
Media Release / Sep 30, 2015
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
In the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of…
Media Release / Sep 28, 2015
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
Media Release / Sep 27, 2015
Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET
In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
Media Release / Sep 25, 2015
Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval
Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart failure trial which…
Media Release / Sep 24, 2015
Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires
New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
Media Release / Sep 24, 2015
Novartis nomme le Dr James E. Bradner Président des Instituts Novartis pour la Recherche Biomédicale suite au prochain départ à la retraite de Mark Fishman
Un nouveau responsable pour continuer de stimuler l'innovation à long terme au sein de la recherche chez Novartis dans des domaines thérapeutiques très variés Bâle, le 24 septembre 2015 -…